ARTICLES

sleep wire
Industry News Product/Vendor Updates

The Sleep Wire 

EnsoData Raises $20M to Accelerate Commercialization of AI-powered Sleep Solutions EnsoData, an innovator in AI healthtech solutions, announced a $20 million Series B financing led by Questa Capital. This new capital will enable EnsoData to accelerate adoption of its AI-powered sleep medicine solutions, improving the sleep care pathway for, in […]

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 1
Sleep Pharmaceuticals Industry News Narcolepsy

Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025

Takeda will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861)1, a potential first-in-class investigational oral orexin receptor 2 (OX2R)-selective agonist in narcolepsy type 1 (NT1), during multiple oral presentations at the World Sleep 2025 Congress in Singapore.   Both the FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002) […]

3 Powerful Takeaways from the 2025 WUN National Summit
WUN Advocacy/Awareness Narcolepsy

The Power of WUN

Attendees traveled from near and far to join us in person and online for the 2025 Wake Up Narcolepsy National Summit in Raleigh-Durham, N.C. Hosted in a different city each year, the summit provides a place where industry professionals, clinicians, individuals with narcolepsy, and family members can come together and […]

NOCTEM Health
SleepWorld Magazine Research/Studies

NOCTEM Health

An estimated one in three adults worldwide experience symptoms of insomnia, yet only a fraction of those suffering have access to specialists trained in cognitive behavioral therapy for insomnia (CBTI)—the gold standard in treatment.1,2  This unmet need has created a major bottleneck in behavioral sleep medicine, where demand far exceeds […]

Avadel Strengthens Portfolio with Exclusive License of Valiloxybate
Sleep Pharmaceuticals

Avadel Pharmaceuticals Strengthens Sleep Medicine Portfolio with Exclusive License of Valiloxybate from XWPharma Ltd

Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, and XWPharma Ltd. (“XWPharma”) together announced today that Avadel has entered into an exclusive global license agreement with XWPharma to develop and commercialize valiloxybate, a GABAB receptor agonist, for all indications, including the treatment of sleep disorders, such […]

Expanding the Sleep Tech Frontier
BRPT Industry News

Expanding the Sleep Tech Frontier

The global field of sleep medicine is at a critical inflection point, and at the heart of it lies a shared challenge—the shortage of qualified sleep technologists. With rising awareness of sleep disorders and their link to chronic health conditions, the demand for structured training and certification has surged, particularly […]